Compare OneSpan Inc (OSPN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Regeneron Pharmaceuticals Inc — how do they compare? OneSpan Inc trades at $17.96 (market cap $652.28M), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 117.1× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (2.94%). Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| OSPN | REGN | |
|---|---|---|
Market Cap | $652.28M | $76.40B |
Volume | 590,167 | 626,381 |
Sector | Technology | Health |
52-Week High | $18.42 | $852.03 |
52-Week Low | $10.15 | $557.73 |
Typical Hold Time | 18 Days | 107 Days |
Enterprise Value | $621.36M | $71.12B |
Dividend Yield | 2.94% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $17.70, down 3.7% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 27.76% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights investor attention and a new product launch, DigipassONE, aimed at authentication modernization.
The outlook remains positive given consistent earnings beats and a strong analyst buy consensus, though risks include negative net cash flow trends and competitive pressures in the technology sector. Revenue growth is modest, but high margins and a reasonable P/E of 10 support valuation. The stock presents a value opportunity with controlled risk.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
